Table 1.
Demographic and clinical characteristics.
| TRS (n = 43) | NTRS (n = 43) | HC (n = 53) |
F or χ2 (p Value ) |
||||
|---|---|---|---|---|---|---|---|
| across three groups | (TRS vs. HC) | (NTRS vs. HC) | (TRS vs. NTRS) | ||||
| Sex (M/F) | 28/15 | 28/15 | 27/26 | 2.74(0.25) | 1.95(0.16) | 1.95(0.16) | 0(1.00) |
| Age (years) | 48..5± 8.9 | 46.5±10.6 | 44.8±9.4 | 1.71(0.18) | 2.79(0.10) | 1.36(0.25) | 0.15(0.70) |
| Education (years) | 12.1± 2.7 | 12.3± 3.0 | 12.3±2.3 | 0.02(0.95) | 0.35(0.56) | 0.03(0.86) | 0.12(0.73) |
| Age of onset (years) | 22.7 ±5.7 | 25.1±6.7 | NA | NA | NA | NA | 3.07(0.08) |
| Duration of illness (years) | 25.3±9.7 | 22.1±12.0 | NA | NA | NA | NA | 1.84(0.18) |
| CPZ equivalent dose (mg/d) | 745.9±227.4 | 470.6±217.9 | NA | NA | NA | NA | 32.86(1.5 × 10−7) |
| PANSS | |||||||
| Positive sub-scores | 23.4±4.3 | 10.95±3.9 | NA | NA | NA | NA | 196.76(1.0 × 10−23) |
| Negative sub-scores | 23.4±7.2 | 14.8±5.3 | NA | NA | NA | NA | 42.41(5.2 × 10−9) |
| General sub-scores | 38.4±8.3 | 23.7±3.6 | NA | NA | NA | NA | 113.66(2.8 × 10−17) |
| Total scores | 85.1±12.6 | 49.1±10.8 | NA | NA | NA | NA | 202.29(4.4 × 10−24) |
| BPRS | 54.1±7.1 | 29.5±7.0 | NA | NA | NA | NA | 260.60(1.8 × 10−27) |
| CGI-SI | 5.8±0.8 | 2.4±0.5 | NA | NA | NA | NA | 525.00(6.9 × 10−38) |
CPZ: Chlorpromazine; PANSS: Positive and negative syndrome scale; BPRS: Brief psychiatric rating scale; CGI-SI: Clinical global impression-severity of illness; TRS: treatment-resistant schizophrenia; NTRS: treatment-responsive schizophrenia; HC: Healthy controls.